Vcanbio Cell & Gene Engineering Corp., Ltd (SHA:600645)

SHA:600645 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	1,502	1,550	1,538	1,507	1,497	1,288
Other Revenue	35.81	35.81	52.07	47.8	37.94	31.38
Revenue	1,538	1,585	1,590	1,555	1,535	1,319
Revenue Growth (YoY)	-4.46%	-0.27%	2.24%	1.27%	16.41%	-4.90%
Cost of Revenue	485.7	497.75	505.02	510.29	473.84	451.09
Gross Profit	1,053	1,088	1,085	1,045	1,061	867.81
Selling, General & Admin	685.49	695.33	719.77	723.4	749.78	632.71
Research & Development	176.89	182.11	184.49	146.12	133.85	111.78
Other Operating Expenses	20.59	19.39	19.19	17.59	16.54	15.49
Operating Expenses	911.44	924.48	946.57	901.67	937.05	774.3
Operating Income	141.08	163.2	138.14	142.93	124.44	93.51
Interest Expense	-4.86	-5.03	-5.02	-4.02	-3.14	-3.77
Interest & Investment Income	25.97	24.4	29.59	18.23	16.21	45.86
Earnings From Equity Investments	-13.23	-14.3	-11.85	-7.96	-	-
Currency Exchange Gain (Loss)	-3.2	-3.2	1.51	-2.37	0.1	2.04
Other Non Operating Income (Expenses)	-2.51	-3.22	1.03	-2	-1.49	-2.05
EBT Excluding Unusual Items	143.25	161.84	153.4	144.82	136.13	135.59
Impairment of Goodwill	-	-	-	-	-19.72	-264.65
Gain (Loss) on Sale of Investments	-30.03	-30.03	-36.09	-0.75	79.09	5.72
Gain (Loss) on Sale of Assets	0.04	1.3	3.67	2.03	0.51	20.4
Asset Writedown	-5.33	-4.68	-0.31	-0.8	-6.26	-
Other Unusual Items	7.54	7.52	11.92	9.9	33.2	13.84
Pretax Income	115.47	135.95	132.59	155.21	222.96	-89.09
Income Tax Expense	42.06	46.59	34.03	48.53	71.75	37.83
Earnings From Continuing Operations	73.41	89.35	98.55	106.68	151.21	-126.92
Minority Interest in Earnings	14.82	11	7.9	6.3	4.11	0.06
Net Income	88.23	100.35	106.45	112.99	155.32	-126.86
Net Income to Common	88.23	100.35	106.45	112.99	155.32	-126.86
Net Income Growth	-19.22%	-5.73%	-5.78%	-27.26%	-	-
Shares Outstanding (Basic)	461	456	463	471	471	470
Shares Outstanding (Diluted)	461	456	463	471	471	470
Shares Change (YoY)	0.84%	-1.45%	-1.69%	0.02%	0.17%	4.01%
EPS (Basic)	0.19	0.22	0.23	0.24	0.33	-0.27
EPS (Diluted)	0.19	0.22	0.23	0.24	0.33	-0.27
EPS Growth	-19.89%	-4.35%	-4.17%	-27.27%	-	-
Free Cash Flow	252.43	217.87	210.4	162.7	193.22	152.64
Free Cash Flow Per Share	0.55	0.48	0.46	0.35	0.41	0.33
Gross Margin	68.42%	68.61%	68.23%	67.18%	69.14%	65.80%
Operating Margin	9.17%	10.29%	8.69%	9.19%	8.11%	7.09%
Profit Margin	5.74%	6.33%	6.70%	7.27%	10.12%	-9.62%
Free Cash Flow Margin	16.41%	13.74%	13.23%	10.46%	12.58%	11.57%
EBITDA	233.09	265.53	281.74	253.74	227.35	196.82
EBITDA Margin	15.15%	16.75%	17.72%	16.32%	14.81%	14.92%
D&A For EBITDA	92.01	102.33	143.6	110.81	102.91	103.31
EBIT	141.08	163.2	138.14	142.93	124.44	93.51
EBIT Margin	9.17%	10.29%	8.69%	9.19%	8.11%	7.09%
Effective Tax Rate	36.43%	34.27%	25.67%	31.26%	32.18%	-
Revenue as Reported	1,538	1,585	1,590	1,555	1,535	1,319
Advertising Expenses	-	30.86	32.98	29.02	32.43	26.79

Source: S&P Global Market Intelligence. Standard template. Financial Sources.